Multiple Sclerosis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Multiple sclerosis Pipeline Insight 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Multiple Sclerosis Treatment Landscape. Click here to read more @ Multiple Sclerosis Pipeline Outlook
Key Takeaways from the Multiple Sclerosis Pipeline Report
In May 2025, Novartis Pharmaceuticals announced a Phase IV study in which breastfeeding mothers treated with ofatumumab and their babies are taking part for up to 1 year. The study consists of a Core Part and a Safety Follow-up Part. The Core Part includes a Screening period and a Sampling period. During the Screening period (up to 4 weeks), the study doctor will assess if mothers can join the study. The Sampling period, during which milk samples and a blood sample will be collected, will last for up to 12 weeks. The Safety Follow-up Part will last for about 9 months, to follow up on health and safety of mothers and their babies.
In May 2025, Hoffmann-La Roche announced a study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab.
In May 2025, Eli Lilly and Company conducted a study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
In May 2025, Biocad announced a clinical study is to assess the long-term efficacy and safety of BCD-132 (divozilimab) in patients with multiple sclerosis who previously participaded in BCD-132-2 and BCD-132-4/MIRANTIBUS studies.
In May 2025, Sanofi conducted a study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.
In May 2025, Biogen organized a study is to assess the efficacy of DMF in Chinese participants with RMS at Week 48. The secondary objectives of the study are to assess the efficacy and safety of DMF in Chinese participants with RMS.
DelveInsight's Multiple Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Sclerosis treatment.
The leading Multiple Sclerosis Companies such as Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others.
Promising Multiple Sclerosis Therapies such as 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others.
Stay informed about the cutting-edge advancements in Multiple Sclerosis treatments. Download for updates and be a part of the revolution in cancer care @ Multiple Sclerosis Clinical Trials Assessment
Multiple sclerosis Emerging Drugs Profile
IMU-838: Immunic Therapeutics
Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. Bolstered by excellent clinical data from the phase II EMPhASIS trial, Immunic believed that vidofludimus calcium has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties.
BIIB091: Biogen
BIIB091 selectively inhibits Burton's tyrosine kinase (BTK), a non-receptor tyrosine kinase that regulates the development and signaling of B cells and myeloid cells hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of another cell of the immune system, the myeloid cells via another receptor of this cell (Fcγ receptor signaling (FcγRs)). Preclinical studies demonstrated BIB091 to be a high potency molecule with good drug-like properties and a safety/tolerability profile suitable for clinical development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple sclerosis.
IMCY-0141: ImCyse
IMCY-0141 is the Company's second clinical-stage compound. This Imotope is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of multiple sclerosis.
NeuroVax: Immune Response BioPharma
NeuroVax contains a combination of three protein fragments (peptides) which appear on the surface of T-cells involved in the immune response in MS. Studies suggested that treatment with NeuroVax stimulates production of certain regulatory T-cells, which in turn decrease the levels of other T-cells which attack myelin. NeuroVax is a Once a Month Dosing injection, safe, tolerable, enhances FOXP3+ Tregs & Regulates Pathogenic T Cells in MS Patients, a first in class disease modifying Multiple Sclerosis Vaccine. NeuroVax IR has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all treated patients. NeuroVax appears to work in part by enhancing levels of Foxp3+ Tregs, which may help regulate expression of pathogenic T cells in MS patients. The three TCR peptides combined in it correspond to one or more TCR gene families which are over expressed in 90% of MS patients.
The Multiple Sclerosis Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Sclerosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment.
Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different Multiple Sclerosis mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market
Learn more about Multiple Sclerosis Drugs opportunities in our groundbreaking Multiple Sclerosis research and development projects @ Multiple Sclerosis Unmet Needs
Multiple Sclerosis Companies
Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others.
Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Multiple Sclerosis Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Discover the latest advancements in Multiple Sclerosis treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives
Scope of the Multiple Sclerosis Pipeline Report
Coverage- Global
Multiple Sclerosis Companies- Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others.
Multiple Sclerosis Therapies- 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others.
Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Multiple Sclerosis Pipeline on our website @ Multiple Sclerosis Emerging Drugs and Companies
Table of Content
Introduction
Executive Summary
Multiple sclerosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Multiple sclerosis – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
IMU-838: Immunic Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
BIIB091: Biogen
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
NeuroVax: Immune Response BioPharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Multiple sclerosis Key Companies
Multiple sclerosis Key Products
Multiple sclerosis- Unmet Needs
Multiple sclerosis- Market Drivers and Barriers
Multiple sclerosis- Future Perspectives and Conclusion
Multiple sclerosis Analyst Views
Multiple sclerosis Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
33 minutes ago
- Globe and Mail
Which country are Canadians visiting instead of the U.S.? Take our business and investing news quiz for the week ending June 6
Welcome to The Globe and Mail's business and investing news quiz. Join us each week to test your knowledge of the stories making headlines. Our business reporters come up with the questions, and you can show us what you know. This week: U.S. President Donald Trump doubled steel and aluminum tariffs and it's no wonder Canadians are still avoiding trips down south. But which country's tourism sector is reaping the benefits of the U.S. travel boycott? Take our quiz and find out.
Globe and Mail
34 minutes ago
- Globe and Mail
The $12.6 Billion Quantum Leap: High-Potential Stocks Under $10 (ZENA, SKYT, LAES, BTQQF)
Quantum computing is emerging as one of the most promising frontiers in technology today. Unlike traditional computers that use bits as the smallest unit of data, quantum computers use quantum bits or qubits, which can exist in multiple states simultaneously. This allows quantum systems to tackle complex problems far beyond the capabilities of classical computers, solving them faster and more efficiently. While often overshadowed by the hype around artificial intelligence, quantum computing is steadily gaining traction. It is driving breakthroughs in areas such as machine learning, image and speech recognition, and optimization problems. The technology's potential is attracting significant investor attention, with some betting it could spark growth on par with the AI revolution. The market for quantum computing is expanding rapidly. According to Fortune Business Insights, the global quantum computing market was valued at $885 million in 2023 and is expected to soar to over $12.6 billion by 2032, growing at an annual rate of nearly 35 percent. This rapid growth highlights the sector's rising importance and opportunity. Within this dynamic landscape, smaller high-tech companies trading under $10 often have the potential to become breakout performers. They offer investors a chance to get in early on the next wave of innovation without the high price tag of established giants. Now, let us explore some of the promising rising stocks in this fast-growing quantum computing sector. Among the most compelling under-the-radar quantum computing stocks under $10, ZenaTech (Nasdaq: ZENA) stands out with its rare blend of AI drone technology, Drone as a Service (DaaS), enterprise software, and quantum innovation. The company reported an impressive 92 percent year-over-year revenue growth in the first quarter of 2025, climbing to $1.13 million from $591,379 in Q1 2024. This surge was driven by organic momentum and key acquisitions in drone services and enterprise software, showcasing a firm that is not only scaling but strategically positioning itself in rapidly expanding markets. ZenaTech operates through its drone-focused subsidiary ZenaDrone and a growing network of global offices in North America, Europe, Taiwan, and the UAE. It develops autonomous AI-powered drones capable of integrating machine learning, predictive modeling, and now, quantum computing. These drones are already in field use across agriculture, logistics, defense, and surveillance applications. But the company's most ambitious and potentially disruptive initiative is its Clear Sky project, which combines AI drone swarms with quantum computing to transform how we predict and respond to extreme weather events. The Clear Sky project aims to address a growing global challenge. In 2024 alone, there were 58 separate billion-dollar weather disasters, including 27 in the United States. These included hurricanes, floods, wildfires, and storms that caused $417 billion in global losses, according to Gallagher Re. ZenaTech's solution uses coordinated drone fleets outfitted with advanced sensors to collect real-time atmospheric data across different layers of the sky. The data is then processed using quantum computing systems that can handle massive, complex datasets at unprecedented speed and resolution. 'Drones with sensors flying at high altitudes can collect data in real time, enabling greater spatial and temporal resolution,' said CEO Shaun Passley, Ph.D. 'This results in more precise, up-to-the-minute weather insights to better anticipate the onset of extreme weather like tornadoes.' AI drone swarms enhance the frequency and localization of measurements, delivering a leap forward in meteorological forecasting capabilities and early disaster warnings. In addition to weather forecasting, ZenaTech is now using this same AI-quantum fusion to address wildfire threats in the US West. The company's drones, equipped with thermal and multispectral sensors and 360-degree LiDAR, are deployed across hundreds of square miles to simulate wildfire spread and optimize emergency responses. A newly acquired land surveying firm in Oregon and partnerships with Native American communities in Wyoming support this initiative, enhancing field data collection and real-world testing environments. The first quarter also marked major product milestones, including the third-generation ZenaDrone 1000 entering scalable production, and the IQ Square drone moving to manufacturing. ZenaTech began work on a heavy-lift, gas-powered ZD 1000 variant for US defense applications and initiated testing of a high-density drone battery and proprietary communications system. The company also ramped up hiring, bringing on 35 new engineers and technicians to expand drone development in the UAE and opened a new drone testing facility in Turkey. ZenaTech's enterprise software business is also advancing, highlighted by its acquisition of Othership, a UK-based workplace management platform. This complements its SaaS offerings and introduces AI and quantum productivity tools aimed at government and business clients. While expenses rose in the first quarter due to rapid expansion, hiring, and R&D investment, the long-term strategy is clear. ZenaTech is building a platform company with national and international scale across drone hardware, software, and quantum-driven analytics. The company is preparing for Green and Blue UAS certification, a necessary step to access US military contracts, and is developing secure, certifiable drone sensors in Taiwan. ZenaTech (Nasdaq: ZENA) is a rare sub-$10 stock with exposure to multiple exponential technologies. With nearly doubled revenues, expanding drone deployments, growing defense ties, and pioneering work in quantum-enhanced weather and wildfire response, the company offers high-upside potential in one of the most dynamic corners of the tech market. SkyWater Technology (NASDAQ: SKYT) is emerging as a pivotal player in the push to restore and expand secure U.S. semiconductor manufacturing. With shares still trading under ten dollars, the company has quietly built serious momentum on multiple fronts, including next-generation quantum breakthroughs, boardroom reinforcements, and a major upcoming acquisition that could reshape its production capabilities. One of SKYT's biggest catalysts came in March when partner D-Wave Quantum published peer-reviewed research in Science validating quantum supremacy in simulation. The research used superconducting qubits fabricated by SkyWater, and the prototype processor outperformed one of the most powerful classical supercomputers in modeling magnetic materials. This milestone underscored SkyWater's role in enabling a major leap in quantum computing. CEO Thomas Sonderman called it 'an unprecedented innovation' and emphasized the importance of expanding foundational node infrastructure in the United States. The partnership between D-Wave and SKYT spans more than a decade, and SkyWater's advanced capabilities in custom material deposition and large-scale fabrication were essential to commercializing the breakthrough. Leadership changes are also adding weight to the bull case for SKYT. In April, the company added three seasoned executives to its board, including Timothy Baxter, former CEO of Samsung North America, who is set to become board chair. Baxter brings deep strategic experience in emerging technologies like AI, 5G, and cloud infrastructure. He is joined by Tammy Miller, a former lieutenant governor and longtime CEO of Border States Electric, and Andrew LaFrence, a former KPMG partner and CFO with life sciences and government manufacturing experience. According to Sonderman, these additions strengthen the company's ability to accelerate its expansion strategy and navigate a fast-changing landscape. SkyWater also appointed Dr. Percy Gilbert as senior vice president of engineering. With a technical background that includes IBM, NXP, and Motorola, Gilbert will play a key role in scaling operations and supporting SKYT's growth in wafer services and advanced technology. Notably, he steps in as the company prepares to close its acquisition of Infineon's Fab 25 facility in Austin. Backed by a supply agreement valued above one billion dollars, this deal could prove transformational. Management believes Fab 25 is uniquely positioned to provide the scale and process flexibility needed to meet foundational semiconductor demand, while aligning tightly with national supply chain security goals. Financially, SkyWater (NASDAQ: SKYT) reported strong sequential growth in wafer services during the first quarter of 2025, driven by adoption of its new ThermaView platform among defense contractors. While budget delays in Washington have temporarily softened the outlook for advanced technology services, management remains confident in year-over-year revenue growth for both business segments and expects to deliver strong adjusted EBITDA and positive non-GAAP EPS for the full year. With the Infineon deal expected to close by mid-year and a ramp in advanced packaging revenues coming in the second half, SkyWater looks well-positioned to unlock meaningful long-term upside. SEALSQ Corp (NASDAQ: LAES) stands out in the post-quantum technology space by developing advanced hardware and software solutions that safeguard against the emerging threat of quantum computing. Their products combine semiconductors, public key infrastructure (PKI), and provisioning services, emphasizing the highest-level quantum-resistant cryptography designed to replace vulnerable traditional encryption methods like RSA and ECC. In May 2025, SEALSQ announced that its flagship QVault Trusted Platform Module (TPM) achieved compliance with ML-DSA-87 and ML-KEM-1024 — the most secure NIST-standardized algorithms (CRYSTALS-Dilithium and CRYSTALS-Kyber) currently available for post-quantum cryptography. These algorithms provide AES-256 equivalent security and are tailored for defense, IoT, and automotive markets that demand the strongest protection for firmware signing, secure communications, and device authentication. The QVault TPM offers a tamper-resistant environment to shield cryptographic keys and operations, certified to stringent standards like FIPS 140-2/3 and Common Criteria EAL5+. Beyond hardware, LAES is pushing boundaries with its space-based quantum initiatives. The company is set to lead the world's first space-based Quantum Key Distribution (QKD) proof-of-concept through the June 2025 launch of WISeSat 2.1. This mission embeds SEALSQ's Quantum RootKey technology into a satellite, paving the way for ultra-secure, sovereign quantum-resistant satellite communications. The WISeSat constellation, backed by a $10 million SEALSQ investment, promises to extend quantum-safe communications and decentralized IoT transactions globally, including remote areas where traditional networks struggle. SEALSQ is also expanding its impact in consumer IoT. Recently, global smart home leader Hager selected SEALSQ's PKI-as-a-Service platform, INeS, to provide device attestation certificates for its Matter-compliant smart home products. INeS delivers post-quantum secure certificates, ensuring long-term protection for billions of connected devices in the smart home ecosystem. With rising cyber threats and the quantum computing horizon looming, SEALSQ's integrated approach across semiconductors, satellite communications, and IoT security positions it as a key player in the next generation of unbreakable digital trust. BTQ Technologies Corp. (OTCQX: BTQQF) is emerging as a serious contender among the rising quantum stocks under $10. Founded by a team of post-quantum cryptographers, the company is building a platform that bridges cryptographic software with purpose-built hardware to defend against the future threats of large-scale universal quantum computers. Recent developments highlight BTQ's commitment to both technical innovation and global engagement. In April, BTQQF signed a Memorandum of Understanding with EntangleTech, a leading quantum education organization in Taiwan. The partnership will support the creation of educational content focused on quantum computing and emerging technologies. BTQ is contributing both funding and expertise, helping EntangleTech produce accessible materials such as videos and podcasts designed to boost quantum literacy. This move underscores BTQ's commitment to public education and international collaboration, positioning the company as a global voice in the quantum space. Shortly after, BTQ announced another MOU with Quandela, a photonic quantum computing company based in France. Together, they will test BTQ's Quantum Sampling Proof-of-Work protocol, a quantum-secure and energy-efficient alternative to traditional blockchain mining. If successful, this collaboration could lay the foundation for a more sustainable and quantum-resilient blockchain future. It also opens the door for commercial applications of Quandela's Belenos quantum processor within BTQ's protocol. More recently, BTQ signed an agreement with ICTK, a South Korean semiconductor security firm known for its PUF-based chip technologies. This partnership will explore the joint development of secure cold wallets and other hardware solutions using BTQ's proprietary CASH architecture. The system is capable of processing up to one million digital signatures per second and encrypting data up to five times faster than competing solutions. Compact, energy-efficient, and quantum-ready, CASH is designed to protect vital systems in finance, telecom, identity, and embedded devices. BTQ Technologies Corp. is not only advancing the science of post-quantum cryptography but also securing partnerships and infrastructure that could give it a real edge in the quantum transition. For investors seeking long-term exposure to quantum resilience and security innovation, BTQ stands out as a stock to watch. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ZenaTech Ltd. to assist in the production and distribution of content related to ZENA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Media Contact Company Name: RazorPitch Contact Person: Mark McKelvie Email: Send Email City: NAPLES State: Florida Country: United States Website:
Globe and Mail
42 minutes ago
- Globe and Mail
2 Growth Stocks to Buy and Hold Forever
Buying growth stocks that you intend to hold forever is a smart strategy. It forces you to think about companies that will still be around in 50 years. This raises the odds that the stock will keep compounding in value over your lifetime, which is the lazy way to get rich without doing much work. If this sounds like a good plan, here are two stocks to consider buying. 1. Amazon Amazon (NASDAQ: AMZN) has profitable revenue streams coming from e-commerce, cloud computing, retail advertising, and third-party fulfillment services. It generated $21 billion in free cash flow on $650 billion of revenue over the last year. The foundation of Amazon's business is its online store, making up 37% of first-quarter revenue. Its wide selection, delivery infrastructure, and large customer base with more than 200 million Prime members give Amazon a strong competitive advantage. Amazon's investments in robotics to automate inventory management and order processing are strengthening its competitive advantage in a $4 trillion global e-commerce market. Amazon continues to push the limits of delivery speeds. In Q1, it set a new record for items delivered the same or next day. It's probably not by accident that this accomplishment follows the unveiling of its next-generation fulfillment center in Shreveport, Louisiana, in 2024. This facility is powered by artificial intelligence (AI) and uses 10 times more robotics than the company's other facilities. Amazon said its new fulfillment center will set a new standard for the retail industry. This is an incredibly innovative company that has progressed from selling out of a garage 30 years ago to using AI to deliver millions of items at blazing speed. That's the kind of business you want to invest in. Amazon 's investments in AI bolster its long-term prospects. Analysts currently expect the company's earnings to grow at an annualized rate of 17% in the coming years, which reflects expectations for improving margins in its retail business, in addition to strong growth from other high-margin services like cloud computing and advertising. Amazon has a lot of levers it can pull to create shareholder returns. 2. Netflix Netflix (NASDAQ: NFLX) stock continues to hit new highs. It has evolved from a DVD-by-mail rental service 20 years ago to a dominant streaming service. Over the last year, the company generated $7 billion in free cash flow on $40 billion of revenue, and it keeps growing. Its growing cash flow paves the way for increasing content spend to keep winning more subscribers. People have varying entertainment preferences, and Netflix can afford to make a wide variety of content that pleases everyone. It spent $17 billion in content production last year and still reported a stellar 22% profit margin. Netflix still has a huge opportunity internationally. Its growing budget will allow it to invest in widening its content offering to appeal to different cultures. Netflix started investing in local infrastructure to support its growth plans a decade ago and is now producing content in more than 50 countries. What's more, Netflix is testing new content formats to widen the viewership. Its livestream of the Taylor-Serrano fight in November was the most-watched professional women's sports event in U.S. history. With more than 700 million people watching content on its platform, Netflix could also see advertising revenue soar in the coming years. Ad-supported subscriber plans come at a lower price point, helping the company expand its audience reach and boost margins at the same time. Analysts expect its earnings to grow at an annualized rate of 22% over the next several years. Netflix's strong brand and high-margin business have the makings of a stock that is going to reward shareholders for many years. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor 's total average return is789% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
